Caga Jashelle, Ramsey Eleanor, Hogden Anne, Mioshi Eneida, Kiernan Matthew C
Neuroscience Research Australia,Randwick,New South Wales,Australia.
Centre for Clinical Governance Research,Australian Institute of Health Innovation,University of New South Wales,Randwick,New South Wales,Australia.
Palliat Support Care. 2015 Aug;13(4):1019-24. doi: 10.1017/S1478951514000881. Epub 2014 Aug 19.
Recognizing depressive symptoms in patients with amyotrophic lateral sclerosis (ALS) remains problematic given the potential overlap with the normal psychological responses to a terminal illness. Understanding mental health and disease-related risk factors for depression is key to identifying psychological morbidity. The present study aimed to determine the prevalence of depressive symptoms in ALS and to explore mental health and disease-related risk factors for depression.
Structured medical and psychiatric history questionnaires and a validated depression scale (Depression, Anxiety, Stress Scale-21) were completed by 27 ALS patients (60% female; 59% limb onset; age 65.11 ± SE 2.21) prior to their initial review at a multidisciplinary clinic. Physical function was assessed with the Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R).
At the time of initial assessment, 44% of patients had a previous psychiatric history, although the majority (62%) reported no symptoms of depression. The mean ALSFRS-R score was 37.78 ± SE 1.22, with an average diagnostic interval of 16.04 ± SE 2.39 months. Logistic regression analysis revealed that the length of the diagnostic interval alone predicted depressive symptoms (χ²(3, n = 26) = 9.21, Odds Ratio (OR) = 1.12, p < 0.05.
The illness experiences of ALS patients rather than established mental health risk factors influence the manifestation of depressive symptoms in the early stages of the disease, with clinical implications for the assessment and treatment of psychological morbidity. Patients with lengthy diagnostic intervals may be prime targets for psychological assessment and intervention, especially in the absence of ALS-specific tests and biomarkers.
鉴于肌萎缩侧索硬化症(ALS)患者的抑郁症状可能与对绝症的正常心理反应重叠,识别这些症状仍然存在问题。了解心理健康和与疾病相关的抑郁风险因素是识别心理疾病的关键。本研究旨在确定ALS患者中抑郁症状的患病率,并探讨心理健康和与疾病相关的抑郁风险因素。
27例ALS患者(60%为女性;59%为肢体起病;年龄65.11±标准误2.21)在多学科诊所进行初次评估前,完成了结构化的医学和精神病史问卷以及一份经过验证的抑郁量表(抑郁、焦虑、压力量表-21)。使用肌萎缩侧索硬化症功能评定量表(ALSFRS-R)评估身体功能。
在初次评估时,44%的患者有既往精神病史,尽管大多数(62%)报告没有抑郁症状。ALSFRS-R的平均得分是37.78±标准误1.22,平均诊断间隔为16.04±标准误2.39个月。逻辑回归分析显示,仅诊断间隔时间就能预测抑郁症状(χ²(3, n = 26) = 9.21,优势比(OR)= 1.12,p < 0.05)。
ALS患者的疾病经历而非既定的心理健康风险因素会影响疾病早期抑郁症状的表现,并对心理疾病评估和治疗具有临床意义。诊断间隔时间长的患者可能是心理评估和干预的主要对象,尤其是在缺乏ALS特异性检测和生物标志物的情况下。